ArticleMedicine2025
Ahmed glaucoma valve implantation for congenital ectropion uveae with glaucoma: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
rationaleCongenital ectropion uveae (CEU) is a rare, nonprogressive anomaly characterized by the proliferation of the iris pigment epithelium on the anterior surface of the iris, often associated with glaucoma. Due to its rarity and complexity, standardized glaucoma surgical management is limited. To our knowledge, the application of glaucoma drainage devices in CEU is rarely documented. Here, we report a case of Ahmed glaucoma valve (AGV) implantation for unilateral CEU associated with glaucoma. PATIENT CONCERNS: A 26-year-old female initially presented with blunt ocular trauma with an intraocular pressure (IOP) of 37 mm Hg in the right eye. After starting glaucoma medication, IOP promptly decreased to 21 mm Hg. However, the patient was subsequently lost to follow-up. DIAGNOSES: A definitive diagnosis was not made due to the limited understanding of CEU at the first visit. Nearly 3 years later, the patient was referred to our hospital again with decreased vision for 6 months and mild distending pain in the right eye. The best-corrected visual acuity was 20/25, IOP was 51 mm Hg, and the cup-to-disc ratio was 0.8. Slit-lamp examination of the right eye revealed 360° ectropion uveae, extending around the pupil to the mid-periphery of the iris, which was an unaltered condition since the first visit. Thus, the patient was diagnosed with CEU and unilateral glaucoma.
interventionsThe AGV implantation surgery with mitomycin C was performed in the right eye. OUTCOMES: The best-corrected visual acuity of the right eye improved to 20/20. IOP stabilized without medications during the entire period of follow-up for 3 years. LESSONS: Although CEU is rare, ophthalmologists should remain vigilant to avoid missed diagnoses due to its high association with glaucoma. AGV implantation with mitomycin C may be considered an effective surgical management for adult patients with late-onset glaucoma secondary to CEU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.